Seguir
Mariano Provencio
Mariano Provencio
Hospital Universitario Puerta de Hierro. Universidad Autónoma de Madrid.
Dirección de correo verificada de salud.madrid.org
Título
Citado por
Citado por
Año
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
63102012
Screening for epidermal growth factor receptor mutations in lung cancer
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
29772009
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ...
New England Journal of Medicine 386 (21), 1973-1985, 2022
13532022
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer
M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ...
Journal of clinical oncology 25 (19), 2747-2754, 2007
6682007
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
6422020
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group
E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ...
Journal of Clinical Oncology 21 (1), 20-27, 2003
5742003
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
R Rosell, KD Danenberg, V Alberola, G Bepler, JJ Sanchez, C Camps, ...
Clinical Cancer Research 10 (4), 1318-1325, 2004
5532004
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations
R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ...
Clinical Cancer Research 17 (5), 1160-1168, 2011
3602011
Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations
JM Silva, G Dominguez, JM Garcia, R Gonzalez, MJ Villanueva, ...
Cancer research 59 (13), 3251-3256, 1999
3581999
Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival
J Silva, V García, A Zaballos, M Provencio, L Lombardía, L Almonacid, ...
European Respiratory Journal 37 (3), 617-623, 2011
3312011
Promoter methylation of the PTEN gene is a common molecular change in breast cancer
JM García, J Silva, C Peña, V Garcia, R Rodríguez, MA Cruz, B Cantos, ...
Genes, Chromosomes and Cancer 41 (2), 117-124, 2004
3092004
Cancer‐associated fibroblast and M 2 macrophage markers together predict outcome in colorectal cancer patients
M Herrera, A Herrera, G Domínguez, J Silva, V García, JM García, ...
Cancer science 104 (4), 437-444, 2013
3022013
IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy
WD Travis, S Dacic, I Wistuba, L Sholl, P Adusumilli, L Bubendorf, P Bunn, ...
Journal of Thoracic Oncology 15 (5), 709-740, 2020
2872020
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III …
V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ...
Journal of clinical oncology 21 (17), 3207-3213, 2003
2692003
Cancer antigen 125 associated with multiple benign and malignant pathologies
C Miralles, M Orea, P Espana, M Provencio, A Sánchez, B Cantos, ...
Annals of Surgical Oncology 10, 150-154, 2003
2582003
Genetic variants associated with cancer therapy–induced cardiomyopathy
P Garcia-Pavia, Y Kim, MA Restrepo-Cordoba, IG Lunde, H Wakimoto, ...
Circulation 140 (1), 31-41, 2019
2532019
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth …
L Paz-Ares, JM Sanchez, A Garcia-Velasco, B Massuti, G Lopez-Vivanco, ...
Journal of Clinical Oncology 24 (18_suppl), 7020-7020, 2006
2412006
First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial
LG Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee, L Urban, RB Caro, ...
Journal of Thoracic Oncology 17 (2), 289-308, 2022
2372022
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
R Rosell, L Perez-Roca, JJ Sanchez, M Cobo, T Moran, I Chaib, ...
PloS one 4 (5), e5133, 2009
2352009
PLCG1 mutations in cutaneous T-cell lymphomas
JP Vaqué, G Gómez-López, V Monsálvez, I Varela, N Martínez, C Pérez, ...
Blood, The Journal of the American Society of Hematology 123 (13), 2034-2043, 2014
2322014
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20